E Tech Group Acquires E-Volve Systems

E-Volve will operate under the name “E-Volve Systems, an E Tech Group Company.” Kevin Stout and Principals Jason Antolovich, Vivek Puthezath will remain with the company, and no significant employment changes are anticipated in E-Volve’s Merrimack, New Hampshire, or Cincinnati, Ohio, offices.

E Tech Group announced today the acquisition of E-Volve Systems, a leading provider of industrial automation, controls engineering and computer systems validation to clients in the life sciences, food and beverage, and consumer products industries.

E-Volve will operate under the name “E-Volve Systems, an E Tech Group Company.” Kevin Stout and Principals Jason Antolovich, Vivek Puthezath will remain with the company, and no significant employment changes are anticipated in E-Volve’s Merrimack, New Hampshire, or Cincinnati, Ohio, offices.

“We are thrilled to add E-Volve Systems to the E Tech Group,” said E Tech CEO Matt Wise. “E-Volve is an outstanding firm with an excellent reputation for quality. Their deep footprint in Life Sciences combined with our extensive client set makes us a clear leader in the space. Additionally, our combined clients and services enables E Tech to offer one of the automation industry’s broadest services sets, from cyber security & OT optimization, through automation design, systems integration, industrial data management and business intelligence with 24/7 support. We fulfill the promise of a one-stop shop for advanced automation.”

“As legacy E Tech and Superior employees prior to founding our company in 2011, we have tremendous respect for E Tech Group and are confident this will be a seamless transition that will quickly pay dividends for clients of both companies,” said E-Volve’s partners in a joint statement. “We’re also excited about the career opportunities other members of the E-Volve team may enjoy as part of a larger, fast-growing organization like E Tech Group.”

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.